![](/img/cover-not-exists.png)
Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
Athanasakis, K., Karampli, E., Retsa, M.P., Theodoropoulou, T., Kyriopoulos, J.Volume:
16
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2013.08.175
Date:
November, 2013
File:
PDF, 59 KB
english, 2013